Clindamycin-Loaded Polyhydroxyalkanoate Nanoparticles for the Treatment of Methicillin-Resistant Staphylococcus Aureus-Infected Wounds

The study explores the use of clindamycin-loaded polyhydroxyalkanoate nanoparticles (Cly-PHA NPs) as a novel treatment for methicillin-resistant Staphylococcus aureus (MRSA)-infected wounds. These nanoparticles, characterized by a mean particle size of 216.2 nm and a drug loading of 6.76%, provide a sustained release of clindamycin over 2 days, resulting in potent antibacterial effects against MRSA. In a mouse model with MRSA-infected full-thickness wounds, Cly-PHA NPs significantly enhanced wound healing by effectively eradicating MRSA from the wound bed. The findings suggest that Cly-PHA NPs could be a promising strategy for treating MRSA infections and promoting wound healing.